CCP 08

Drug Profile

CCP 08

Alternative Names: CCP-08

Latest Information Update: 24 Dec 2016

Price : $50

At a glance

  • Originator Vernalis
  • Developer Tris Pharma
  • Class Antitussives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Common cold; Cough

Most Recent Events

  • 21 Feb 2017 Versalis expects approval of NDA by US FDA for CCP 08 for Common cold and Cough
  • 21 Dec 2016 FDA assigns PDUFA action date of 04/08/2017 for CCP 08 for Cold
  • 21 Dec 2016 FDA assigns PDUFA action date of 04/08/2017 for CCP 08 for Cough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top